Table 5 |
||
|
Odds ratio estimates of 28-day mortality for patients receiving DrotAA |
||
|
Variable |
Odds ratio estimate (95% CI) |
P value |
|
|
||
|
Age, years |
||
|
|
||
|
≤49 vs 50 to 64 |
0.524 (0.2203 to 1.2461) |
0.144 |
|
|
||
|
≤49 vs 65 to 74 |
0.251 (0.102 to 0.617) |
0.003* |
|
|
||
|
≤49 vs ≥75 |
0.269 (0.106 to 0.678) |
0.005* |
|
|
||
|
50 to 64 vs 65 to 74 |
0.479 (0.2146 to 1.0676) |
0.072 |
|
|
||
|
50 to 64 vs ≥75 |
0.513 (0.2226 to 1.1802) |
0.116 |
|
|
||
|
65 to 74 vs ≥75 |
1.071(0.4524 to 2.5346) |
0.876 |
|
|
||
|
Time to treatment |
||
|
|
||
|
Delay in time from first sepsis-induced organ dysfunction to start of study drug (six-hour intervals) |
1.231 (1.053 to 1.439) |
0.009* |
|
|
||
|
Laboratory values |
||
|
|
||
|
Increase in creatinine from baseline to day 1 (50 μmol/L intervals) |
1.317 (1.033 to 1.679) |
0.026* |
|
|
||
|
Increase in platelets from baseline to day 1 (50 × 109/L unit intervals) |
0.658 (0.442 to 0.978) |
0.039* |
|
|
||
|
* statistically significant. CI = confidence interval; DrotAA = Drotrecogin alfa activated |
||
|
Hodder et al. Critical Care 2009 13:R78 doi:10.1186/cc7893 |
||
